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ABSTRAK
Reseptor estrogen (ER), reseptor progesterone (PR) dan reseptor faktor ketumbuhan 
epidermal manusia 2 (HER2) immunohistokimia adalah penanda penting dan 
berperanan di dalam pengurusan pesakit yang menghidap neoplastik payudara. Di 
dalam kajian ini, kami membandingkan kadar konkordan ER, PR, dan HER2 diantara 
biopsi jarum teras dan biopsi eksais pada tisu neoplastik payudara melibatkan 
pesakit pesakit Pusat Perubatan Universiti Kebangsaan Malaysia (PPUKM) yang 
di diagnosa diantara bulan Januari 2002 sehingga Disember 2012. Seramai 93 
pesakit wanita yang menjalani biopsi jarum teras dan kemudiannya biopsi eksais 
termasuk di dalam kajian retrospektif ini. Kajian immunohistokimia telah digunakan 
untuk menentukan pewarnaan ER, PR dan HER2. Pewarnaan ER dan PR telah 
dianalisa menggunakan skor Allred (0 hingga 8) manakala analisa pewarnaan HER2 
menggunakan sistem skor 0 hingga 3+. Skor keputusan dibanding antara kedua 
biopsy tersebut untuk menentukan kadar konkordan. Sebanyak 93 sampel berjaya 
dibandingkan diantara kedua biopsi tersebut untuk pewarnaan immunohistokimia 
ER dan PR. Kadar konkordan ER adalah sebanyak 80 kes (86%) dan 13 kes (14%) bagi 
yang tidak konkordan. Kadar konkordan PR adalah sebanyak 82 kes (88.2%) dan 
11 kes (11.8%) bagi yang tidak konkordan. Sebanyak 87 sampel telah dibandingkan 
untuk kajian pewarnaan immunohistokima HER2 dan kadar konkordan adalah 
sebanyak 62 kes (71.3%) dan 25 kes (28.7%) bagi yang tidak konkordan. Di dalam 
kajian ini, kadar konkordan diantara biopsi tisu jarum teras dan biopsi eksais bagi ER 
dan PR adalah tinggi. Manakala, kadar konkordan untuk pewarnaan HER2 adalah 
kurang konsisten.  Kesimpulannya, analisa immunohistokimia untuk biopsi tisu 
jarum teras dapat meramal keputusan penanda pada tisu biopsy eksais di dalam 
penyakit neoplastik payudara. 
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Kata kunci:  neoplastik payudara, biopsi tisu jarum teras, reseptor estrogen, reseptor 
progesterone, HER2
ABSTRACT
Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth 
factor receptor 2 (HER2) immunohistochemistry are important markers in the 
management of patient with breast carcinoma. In this study, we determine the 
concordance rate of ER, PR and HER2 immunohistochemistry markers between 
core needle biopsy (CNB) and excisional biopsy (EB) of breast carcinoma in patients 
of Universiti Kebangsaan Malaysia Medical Centre (UKMMC) from January 2002 
until December 2012. A total of 93 female patients with CNB and subsequent EB 
were included in this retrospective descriptive study. Immunohistochemistry is 
used to determine ER, PR and HER2. ER and PR was graded using Allred score (0 to 
8) while HER2 was scored from 0 to 3+. The markers between these two biopsies 
were compared to determine the concordance rate. In ER and PR, 93 samples 
were compared. ER was concordant in 80 cases (86.0%) and 13 cases (14.0%) was 
discordant. PR was concordant in 82 cases (88.2%) and discordant in 11 cases 
(11.8%). In HER2, 87 samples were compared and 62 cases (71.3%) were concordant 
while 25 cases (28.7%) were discordant. Concordance between CNB and EB was 
high for ER and PR. However, concordance rate for HER2 immunohistochemistry 
was less consistent. Overall, immunohistochemical analyses of CNB reflect the 
tumour marker status of the excised specimen.
Keywords: breast carcinoma, core needle biopsy, estrogen receptor, progesterone 
receptor, HER2
from CNB has been used as biologic 
markers in breast cancers for predicting 
response to specific therapeutic agents. 
Similarly, HER2 over expression has 
been associated with worse prognosis 
in newly diagnosed patients with breast 
carcinoma, and is a determinant of 
response to trastuzumab (Arnedos et 
al. 2009). However, challenges may 
arise as analysing HR markers on 
CNB containing small tissue samples 
may not accurately reflect the overall 
biologic profile of the heterogenous 
tumour. Thus, HR markers on CNB 
may lead to false negative or positive 
results. When “false negative” HR test 
INTRODUCTION
Core needle biopsy (CNB) is widely 
used in routine preoperative practice as 
part of the triple assessment in patients 
with suspected breast carcinoma (Li et 
al. 2012; Wai et al. 2013). Studies have 
reported good concordance rate of 91%-
100% between CNB and excisional 
biopsy (EB) for diagnosis of breast 
carcinoma with a specificity rate ranging 
from 96% to 100% (Li et al. 2012). 
 Immunohistochemical hormonal 
receptor (HR) markers such as estrogen 
receptor (ER), progesterone receptor (PR) 
and HER2 performed on tumor samples 
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results are found, these deprive women 
of the proven benefits of endocrine 
therapies and may lead to choosing 
unnecessary chemotherapy treatments 
with significant financial costs and 
toxicities (Uy et al. 2010).
 In the light of false negative or false 
positive HR markers that may be found 
on CNB, the main aim of the present 
study was to compare the status of ER, 
PR and HER2 markers performed on 
CNB with the immunohistochemical 
results in the subsequent mastectomy/
wide local excision/lumpectomy (EB) for 
patients diagnosed with breast cancer. 
More specifically, this study aimed to 
determine the level of concordance 
between hormonal status identified on 
CNB and EB performed in one of the 
local teaching hospitals in Malaysia.
MATERIALS AND METHODS
PATIENTS AND SAMPLES
A retrospective cohort reviewing 
data and medical records of patients 
diagnosed with breast carcinoma 
from January 2002 until December 
2012 in UKMMC was performed. 
The study was approved by the UKM 
Medical Centre Ethics Committee/
Institutional Review Board (UKM 
Ethics Committee Reference No: UKM 
1.5.3.5/244/FF-077-2013). A total of 
107 female patients with CNB and 
subsequent EB diagnosed with primary 
breast carcinoma were included in 
this descriptive study.  Patients who 
had local recurrent or non-primary 
carcinoma were totally excluded from 
this study. Patients who had received 
neoadjuvant radio or chemotherapy or 
hormonal treatment between CNB and 
the final excised specimens were also 
excluded from this study.
ER, PR AND HER2 DETERMINATION
Immunohistochemistry was used to 
determine ER, PR and HER2 hormonal 
status. ER and PR were graded using 
Allred score from 0 to 8 and scores of 
more than 2 were considered positive. 
HER2 was scored from 0 to 3+. 
Scoring of 2+ and 3+ in HER2 status 
analysis were taken as positive while 
0 and 1+ was considered negative. 
The final results between CNB and 
EB were compared to determine the 
concordance and discordance rate.
STATISTICAL ANALYSIS
The concordance rate, sensitivity, 
specificity, positive and negative 
predictive value were compared using 
SPSS version 19 by considering CNB 
as test assessment and EB as the gold 
standard. 
RESULTS
CONCORDANCE RATE
A total of 93 samples were included in 
this study. A total of 76 patients from the 
93 samples analysed, had infiltrating 
ductal carcinoma, diagnosed both on 
CNB and EB (81% respectively). 
 In CNB, PR was scored as positive 
in 65 (70%) and negative in 28 (30%) 
of the cases. In the EB, PR was positive 
in 62 (67%) of the cases and negative 
in 31 (33%). Discordance of PR status 
between CNB and EB was seen in 11 
cases (11.8%). 
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 ER status was 53% positive on 
CNB compared to 48% in the excised 
specimen. Only 12 samples were 
discordant (14%). 8 of the 12 discordant 
samples showed ER positivity on CNB 
but negative on EB.  The remaining four 
discordant samples were ER negative 
on CNB but positive on EB. 
 Only 87 samples were available for 
HER2 status assessment. Fourty nine 
(56.3%) samples showed HER2 positivity 
on CNB and 38 (43.7%) samples were 
negative for HER2.  In the EB, 39 
samples were HER2 positive (44.8%) 
and 48 were negative (55.2%). A total 
of 26 samples were discordant with a 
discordant rate of 28.7%. Eighteen of 
these discordant samples showed HER2 
positivity on CNB but were negative 
on EB.  Summarized results of these 
findings were shown in Table 1.
SENSITIVITY AND SPECIFICITY OF 
CNB AND EB IN DETECTING ER, 
PR AND HER2 STATUS IN BREAST 
CARCINOMA
CNB was as sensitive as EB in 
determining ER and PR status. 
However, the sensitivity in determining 
HER2 on CNB was less consistent.  The 
rates of sensitivity, specificity, positive 
and negative predictive values were 
summarized in Table 2 with EB as the 
reference for each marker.
DISCUSSION
In routine preoperative practice in 
UKMMC, CNB is often used as part 
of a triple assessment in patients 
with suspected breast carcinoma. 
The expression of these markers 
will guide the Clinician in the 
Table 1: Concordance between CNB and EB for ER, PR and HER2 results
CNB
EB
Total Concordance rate (%) p value
Positive Negative
ER
86 1
Positive 41 8 49
Negative 4 40 44
Total 45 48 93
K=0.84
PR
88.2 1
Positive 58 7 65
Negative 4 24 28
Total 62 31 93
K=0.89
HER2
71.3 0.9
Positive 31 18 49
Negative 8 30 38
Total 39 48 87
K=0.70
p<0.05 =significant
K= kappa value
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therapeutic management of the 
patient. Previous studies concluded 
that immunohistochemical results from 
CNB tend to be less reliable than those 
analysed on excised specimens as CNB 
represent limited sample of tissue with 
possible tumour heterogeneity (Burge 
et al. 2006; Arnould et al. 2012). 
 CNB and EB samples from patients 
assessed in this study was not subjected 
to any mode of preoperative treatment, 
as treatment have been known to alter 
the tumour biologic marker such as ER, 
PR and HER2 (Honkoop et al. 1997). 
However, the tumour marker alterations 
seen in treated specimens may not be 
consistent with HER2. More recently, 
HER2 status was shown to remain 
unchanged when preneoadjuvant 
and post neoadjuvant specimens are 
compared (D’Alfonso et al. 2010).
 Previous studies found concordance 
rates for CNB and surgically excised 
specimens range between 81.3% to 
100% for ER, between 42% to 89% for 
PR and from 86.9% to 100% for HER2 
(Burge et al. 2006; Sutela et al. 2008; 
Wood et al. 2007; Tamaki et al. 2010). 
In agreement with previous findings 
(Burge et al. 2006; Wood et al. 2007; 
Sutela et al. 2008; Ricci et al. 2012), the 
present study found good concordance 
between CNB and EB for ER and PR. 
Previous reports have also found that 
the concordance rate between CNB and 
EB for ER was higher than PR (Arnedos 
et al. 2009). However, in the present 
study, concordance rate between CNB 
and EB for PR was slightly higher than 
that seen for ER, possibly due to better 
fixation in the CNB specimen.
 In the present study, discordance 
between CNB and EB for ER was 14% 
and this finding is consistent with a 
previous study (Connor et al. 2002). 
False negativity for ER was seen in four 
cases, indicating that all ER negative 
results on CNB should be further 
confirmed with EB. As previously 
highlighted by Connor et al. (2002), 
false positivity for ER observed in eight 
cases of this study suggest sampling 
error within the tumour periphery and 
possibly poor fixation in the excised 
specimen.
 While comparing previous studies 
(Wood et al. 2007; Tamaki et al. 2010; 
Ricci et al. 2012), the concordance 
rate between CNB and EB for HER2 
in this study was lower than that seen 
for ER and PR and with a much lower 
sensitivity and specificity rates. The less 
consistent concordance rate for HER2 
was possibly due to limited number of 
samples analysed in this study as well 
as intratumour heterogeneity. Given 
the limitation of tumour diversity, 
the concordance rates appear to be 
Table 2: Sensitivity, specificity, positive and negative predictive value for CNB 
compared with EB
Rate ER (%) 95%CI PR (%) 95%CI HER2 (%) 95% CI
Sensitivity 91.1 0.852-0.968 93.5 0.8849-0.9851 79.4 0.6329-0.9551
Specificity 83.3 0.754-1.584 77.4 0.6890-0.8590 62.5 0.5199-0.7301
Positive predictive value 83.7 0.765-1.605 89.2 0.8289-0.9551 63.3 0.5246-0.7414
Negative predictive value 90.9 0.852-1.762 85.7 0.7859-0.9281 78.9 0.6292-0.9488
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dependent on the number of cores 
analysed in that the higher number 
of cores are analysed, the more 
concordant are the tumour markers 
between EB and CNB (Tamaki et al. 
2010).
 Although, good concordance rates 
between CNB and ER were found in the 
present study, all of these findings were 
not found to be significant, possibly 
due to several limitations that may have 
potentially resulted such as limited 
number of sampling. In addition, 
differences in immunohistochemistry 
assays and fixative procedure may 
have also influenced the findings of 
this study. Breast cancers with HER2 
2+ on immunohistochemistry are 
considered equivocal and therefore 
should undergo fluorescence in situ 
hybridization (FISH) or chromogenic 
in situ hybridization (CISH) methods 
for confirmation (Arnould et al. 2012). 
However, in the present study, FISH/
CISH status of HER2 2+ cases were 
not directly accessible due to time 
constraint and so were considered 
as positive for ease of analysis. The 
assumption of HER2 2+ cases as truly 
positive may have caused selection 
bias in this study and possibly the high 
discordant rates seen in HER2.
CONCLUSION
In conclusion, ER and PR 
immunohistochemistry performed on 
CNB produce results which accurately 
reflect those assessed on EB. The 
concordance rate for HER2 was less 
consistent, suggesting intratumoural 
heterogeneity among contributing 
factors. Concurrent analysis of HER2 
with FISH/CISH on breast cancers is 
required for HER2 2+ cases given the 
high discordant rates between EB and 
CNB.
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